EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate

Stephen C De Rosa, Kristen W Cohen, Matthew Bonaparte, Bo Fu, Sanjay Garg, Catherine Gerard, Paul A Goepfert, Ying Huang, Daniel Larocque, M Juliana McElrath, Daryl Morris, Robbert Van der Most und 2 weitere

Clinical & Translational Immunology · 2022-01 · 11 (1)

DOI: 10.1002/cti2.1360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 11.01.2022. Verfasst von Stephen C De Rosa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division Fred Hutchinson Cancer Research Center Seattle WA USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We previously described the Phase I‐II evaluation of SARS‐CoV‐2 recombinant protein candidate vaccine, CoV2‐PreS‐dTM, with AF03‐ or AS03‐adjuvant systems (ClinicalTrials.gov, NCT04537208). Here, we further characterise the cellular immunogenicity profile of this vaccine candidate using a whole‐blood secretion assay in parallel to intracellular cytokine staining (ICS) of cryopreserved peripheral blood mononuclear cells (PBMCs).

Methods

A randomly allocated subset of 90 healthy, SARS‐CoV‐2‐seronegative adults aged ≥ 18 years who had received (random allocation) one or two separate injections (on study day [D]1 and D22) of saline placebo or CoV2‐PreS‐dTM formulated with AS03 or AF03 were included. Cytokine secretion was assessed using a TruCulture ® whole‐blood stimulation system in combination with multiplex bead array, and intracellular cytokine profiles were evaluated on thawed PBMCs following ex vivo stimulation with recombinant S protein at pre‐vaccination (D1), post‐dose 1 (D22) and post‐dose 2 (D36).

Results

Both methods detected similar vaccine‐induced responses after the first and second doses. We observed a Th1 bias (Th1/Th2 ratio > 1.0) for most treatment groups when analysed in whole blood, mainly characterised by increased IFN‐γ, IL‐2 and TNF‐α secretion. Among participants aged ≥ 50 years, the Th1/Th2 ratio was higher for those who received vaccine candidate with AS03 versus AF03 adjuvant. ICS revealed that this higher Th1/Th2 ratio resulted from higher levels of IFN‐γ expression and that the vaccine induced polyfunctional CD4 + T cells.

Conclusions

The whole‐blood cytokine secretion assay is a high‐throughput alternative for assessing the quantity and character of vaccine‐induced cellular responses.

Schlagwörter

Stichwörter der Autor:innen

AF03AS03CoV2‐PreS‐dTMSARS‐CoV‐2 recombinant protein candidate vaccineadjuvantcell‐mediated immunityintracellular cytokine stainingmultiplex bead arraywhole‐blood cytokine secretion assay

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division Fred Hutchinson Cancer Research Center Seattle WA USA.
  • Global Clinical Immunology Sanofi Pasteur Swiftwater PA USA.
  • Biostatics Sanofi Pasteur Swiftwater PA USA.
  • R&D Operations Sanofi Pasteur Swiftwater PA USA.
  • R&D GlaxoSmithKline Vaccines Rixensart Belgium.
  • Department of Medicine University of Alabama at Birmingham Birmingham AL USA.

ORCID-Profile: Anke Pagnon

Förderung

  • NIAID NIH HHS

Zitieren

APA

De Rosa, S. C., Cohen, K. W., Bonaparte, M., Fu, B., Garg, S., Gerard, C., Goepfert, P. A., Huang, Y., Larocque, D., McElrath, M. J., Morris, D., Van der Most, R., de Bruyn, G., & Pagnon, A. (2022). Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate. Clinical & Translational Immunology, 11(1). https://doi.org/10.1002/cti2.1360

Vancouver

De Rosa SC, Cohen KW, Bonaparte M, Fu B, Garg S, Gerard C, et al. Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate. Clinical & Translational Immunology. 2022;11(1). doi:10.1002/cti2.1360

BibTeX
@article{DeRosa2022,
  author = {De Rosa, Stephen C and Cohen, Kristen W and Bonaparte, Matthew and Fu, Bo and Garg, Sanjay and Gerard, Catherine and Goepfert, Paul A and Huang, Ying and Larocque, Daniel and McElrath, M Juliana and Morris, Daryl and Van der Most, Robbert and de Bruyn, Guy and Pagnon, Anke},
  title = {Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate},
  journal = {Clinical & Translational Immunology},
  year = {2022},
  volume = {11},
  number = {1},
  doi = {10.1002/cti2.1360}
}
Kostenlos starten →